Alpha 2.0
Login Register
» Articles » PMID: 34528453

Challenges and Opportunities for PROTAC Delivery

Overview
Journal Future Med Chem
Specialties Chemistry
Pharmacy
Date 2021 Sep 16
PMID 34528453
Citations 6
Authors
Andrew B Benowitz
Paul T Scott-Stevens
John D Harling
Affiliations
Soon will be listed here.
Citing Articles

Optimizing Antitumor Effect of Triple-Negative Breast Cancer via Rosmarinic Acid-β-Cyclodextrin Inclusion Complex.

Li Y, Inam M, Hasan M, Chen K, Zhang Z, Zhu Y Pharmaceutics. 2024; 16(11).

PMID: 39598532 PMC: 11597731. DOI: 10.3390/pharmaceutics16111408.

Targeted protein degradation: advances in drug discovery and clinical practice.

Zhong G, Chang X, Xie W, Zhou X Signal Transduct Target Ther. 2024; 9(1):308.

PMID: 39500878 PMC: 11539257. DOI: 10.1038/s41392-024-02004-x.

Cocrystallization of Gefitinib Potentiate Single-Dose Oral Administration for Lung Tumor Eradication via Unbalancing the DNA Damage/Repair.

Inam M, Yang Y, Hu J, Zheng J, Deng W, Zhou Y Pharmaceutics. 2023; 15(12).

PMID: 38140054 PMC: 10747925. DOI: 10.3390/pharmaceutics15122713.

Antibody-Proteolysis Targeting Chimera Conjugate Enables Selective Degradation of Receptor-Interacting Serine/Threonine-Protein Kinase 2 in HER2+ Cell Lines.

Chan K, Sathyamurthi P, Queisser M, Mullin M, Shrives H, Coe D Bioconjug Chem. 2023; 34(11):2049-2054.

PMID: 37917829 PMC: 10655034. DOI: 10.1021/acs.bioconjchem.3c00366.

Solubility Enhanced Formulation Approaches to Overcome Oral Delivery Obstacles of PROTACs.

Postges F, Kayser K, Appelhaus J, Monschke M, Gutschow M, Steinebach C Pharmaceutics. 2023; 15(1).

PMID: 36678785 PMC: 9863516. DOI: 10.3390/pharmaceutics15010156.